

# Anne Cm Pizard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8476477/publications.pdf>

Version: 2024-02-01

44  
papers

2,830  
citations

201385

27  
h-index

264894

42  
g-index

44  
all docs

44  
docs citations

44  
times ranked

4703  
citing authors

#	ARTICLE	IF	CITATIONS
1	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	1.9	46
2	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart "OMics"™ in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	1.0	77
3	The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. Journal of Cardiac Failure, 2021, , .	0.7	3
4	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case"control analyses. Clinical Research in Cardiology, 2020, 109, 22-33.	1.5	19
5	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. Heart, 2019, 105, 307-314.	1.2	28
6	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	1.6	63
7	Cohort Profile: Rationale and design of the fourth visit of the STANISLAS cohort: a familial longitudinal population-based cohort from the Nancy region of France. International Journal of Epidemiology, 2018, 47, 395-395j.	0.9	33
8	Eplerenone treatment alleviates the development of joint lesions in a new rat model of spontaneous metabolic-associated osteoarthritis. Annals of the Rheumatic Diseases, 2018, 77, 315-316.	0.5	19
9	Response to: "Spontaneous hypertensive rat exhibits bone and meniscus phenotypes of osteoarthritis: is it an appropriate control for MetS-associated OA?"™ by Chan and Wen. Annals of the Rheumatic Diseases, 2018, 77, e26-e26.	0.5	0
10	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	1.4	21
11	In need of signalling pathway data. European Journal of Heart Failure, 2018, 20, 1202-1204.	2.9	0
12	Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure, 2017, 19, 177-191.	2.9	280
13	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. European Journal of Heart Failure, 2017, 19, 974-986.	2.9	29
14	Risk for Incident Heart Failure: A Subject"Level Meta"Analysis From the Heart "eOMics"™ in AGEing (HOMAGE) Study. Journal of the American Heart Association, 2017, 6, .	1.6	41
15	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the <sc>EMPHASIS"HF</sc> trial. European Journal of Heart Failure, 2017, 19, 1186-1197.	2.9	75
16	The Multifaceted Role of the Lysosomal Protease Cathepsins in Kidney Disease. Frontiers in Cell and Developmental Biology, 2017, 5, 114.	1.8	55
17	Preventive and chronic mineralocorticoid receptor antagonism is highly beneficial in obese SHHF rats. British Journal of Pharmacology, 2016, 173, 1805-1819.	2.7	18
18	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	2.9	109

#	ARTICLE	IF	CITATIONS
19	Tissue kallikrein is required for the cardioprotective effect of Cyclosporin A in myocardial ischemia in the mouse. <i>Biochemical Pharmacology</i> , 2015, 94, 22-29.	2.0	8
20	Simultaneous Characterization of Metabolic, Cardiac, Vascular and Renal Phenotypes of Lean and Obese SHHF Rats. <i>PLoS ONE</i> , 2014, 9, e96452.	1.1	11
21	Opposite Predictive Value of Pulse Pressure and Aortic Pulse Wave Velocity on Heart Failure With Reduced Left Ventricular Ejection Fraction. <i>Hypertension</i> , 2014, 63, 105-111.	1.3	82
22	Disseminated Arterial Calcification and Enhanced Myogenic Response Are Associated With Abcc6 Deficiency in a Mouse Model of Pseudoxanthoma Elasticum. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1045-1056.	1.1	26
23	Smooth Muscle Cell Mineralocorticoid Receptors Are Mandatory for Aldosteroneâ€™Salt to Induce Vascular Stiffness. <i>Hypertension</i> , 2014, 63, 520-526.	1.3	97
24	Selective Involvement of Serum Response Factor in Pressure-Induced Myogenic Tone in Resistance Arteries. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 339-346.	1.1	16
25	A New Pyrroline Compound Selective for $\alpha$ -Imidazoline Receptors Improves Metabolic Syndrome in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 370-380.	1.3	15
26	Aspirin inhibits human bradykinin B2 receptor ligand binding function. <i>Biochemical Pharmacology</i> , 2008, 75, 1807-1816.	2.0	4
27	Lamin A/C haploinsufficiency causes dilated cardiomyopathy and apoptosis-triggered cardiac conduction system disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 44, 293-303.	0.9	147
28	Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney. <i>Biological Chemistry</i> , 2008, 389, 701-706.	1.2	14
29	Tissue Kallikrein Is Involved in the Cardioprotective Effect of AT1-Receptor Blockade in Acute Myocardial Ischemia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 323, 210-216.	1.3	46
30	Tbx5-dependent rheostatic control of cardiac gene expression and morphogenesis. <i>Developmental Biology</i> , 2006, 297, 566-586.	0.9	164
31	Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. <i>Nature Genetics</i> , 2005, 37, 418-422.	9.4	197
32	Connexin 40, a Target of Transcription Factor Tbx5, Patterns Wrist, Digits, and Sternum. <i>Molecular and Cellular Biology</i> , 2005, 25, 5073-5083.	1.1	41
33	N-linked glycosylation of the human bradykinin B2 receptor is required for optimal cell-surface expression and coupling. <i>Biological Chemistry</i> , 2004, 385, 49-57.	1.2	41
34	Whole-mount In Situ Hybridization and Detection of RNA s in Vertebrate Embryos and Isolated Organs. <i>Current Protocols in Molecular Biology</i> , 2004, 66, Unit 14.9.	2.9	24
35	The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system. <i>Development (Cambridge)</i> , 2004, 131, 4107-4116.	1.2	188
36	Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy. <i>Circulation</i> , 2003, 107, 2850-2856.	1.6	300

#	ARTICLE	IF	CITATIONS
37	A Novel Protein-Protein Interaction between a G Protein-coupled Receptor and the Phosphatase SHP-2 Is Involved in Bradykinin-induced Inhibition of Cell Proliferation. <i>Journal of Biological Chemistry</i> , 2002, 277, 40375-40383.	1.6	59
38	Loss-of-Function Polymorphism of the Human Kallikrein Gene with Reduced Urinary Kallikrein Activity. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 968-976.	3.0	69
39	Palmitoylation of the Human Bradykinin B2 Receptor Influences Ligand Efficacy. <i>Biochemistry</i> , 2001, 40, 15743-15751.	1.2	27
40	Determination of Bradykinin B2 Receptor in Vivo Phosphorylation Sites and Their Role in Receptor Function. <i>Journal of Biological Chemistry</i> , 2001, 276, 40431-40440.	1.6	86
41	Bradykinin-induced Internalization of the Human B2Receptor Requires Phosphorylation of Three Serine and Two Threonine Residues at Its Carboxyl Tail. <i>Journal of Biological Chemistry</i> , 1999, 274, 12738-12747.	1.6	95
42	Activation of mitogen-activated protein kinase by the bradykinin B2receptor is independent of receptor phosphorylation and phosphorylation-triggered internalization. <i>FEBS Letters</i> , 1999, 451, 337-341.	1.3	26
43	Negative Cooperativity in the Human Bradykinin B2Receptor. <i>Journal of Biological Chemistry</i> , 1998, 273, 1309-1315.	1.6	46
44	Receptors for kinins in the human isolated umbilical vein. <i>British Journal of Pharmacology</i> , 1996, 118, 289-294.	2.7	85